Zafgen Lines Up $86M IPO to Bankroll Obesity Drug Push
Ben Fidler Zafgen signaled an IPO was likely on the way last year when it added firms like RA Capital, which typically back public companies, to its pool of …
View ArticleHow A Kidney Drug Almost Torpedoed Concert Pharma’s IPO
Ben Fidler [Updated, 4/27/14, 10:49 am ET] Drug development is a humbling thing. Hard as you might try, the numbers show that 90 percent of the time, you’ll …
View ArticleAt Two-Year Mark, JOBS Act Is Regulation Even A Biotech Can Love
Alex Lash It’s been two years since President Obama signed the Jumpstart Our Business Startups (JOBS) Act into law and revamped the rules that govern private companies trying to raise …
View ArticleSan Diego’s Ambrx Files for IPO to Advance Antibody-Drug Conjugates
Bruce V. Bigelow [Corrected 5/6/14, 11 am. See below.] San Diego-based Ambrx, a biotech company with a new approach to developing protein therapeutics for treating, cancers, diabetes, and other …
View ArticleNavigating JOBS, Wrangling Investors: A Biotech CFO Roundtable
Alex Lash In biotech, the visionary scientists and serial entrepreneurs often—arguably too often—get described as “rock stars.” The financial guys… well, not so much. But in a business where …
View ArticleSan Diego’s Ambrx Withdraws IPO, Citing Market Conditions
Bruce V. Bigelow Ambrx, a San Diego biotech developing antibody-drug conjugates to treat solid tumors and other diseases, said today it is withdrawing its planned IPO because of current market …
View ArticleAlkermes Spinoff Civitas, Poised for IPO, Sells to Acorda for $525M
Ben Fidler Civitas Therapeutics was all set to become the latest in the long line of biotechs in 2014 to go public. Then, apparently, it got an offer from Ardsley, …
View ArticleOne Week to Boston’s Life Science Disruptors—Check Out the Agenda
Editors It’s just one week to our annual fall biotech event—where the founders and lead investors of three of Boston’s hottest companies share their stories of trying to build great …
View ArticleBig Events, Exits Raising Boston’s Innovation Profile at Year’s End
Gregory T. Huang Boston’s stock as an innovation cluster is on the rise. At least in the eyes of the outside world. In addition to increased interest in the region’s (Read more...)
View ArticleDevice-Maker BeneChill Seeks to Raise $14.6M Through IPO
Bruce V. Bigelow BeneChill, a startup established in San Diego eight years ago to develop a rapid-chilling technology to treat patients suffering from heart attacks and brain injury, intends (Read...
View ArticleAltheaDx, with Personalized Medicine Diagnostics, Files for IPO
Bruce V. Bigelow San Diego-based AltheaDx, which uses diagnostic tests and bioinformatics to help doctors identify the optimal drugs based on a patient’s genetic make-up, plans to raise as much (Read...
View Article14 for ’14: Xconomy’s Top Innovation Stories of the Year
Gregory T. Huang It has been quite a year for one-word headlines: Ebola, Sony, Uber, WhatsApp, to name a few. Behind those headlines are complex issues in business and technology (Read more...)
View ArticleTracon Files for $57.5M IPO to Move Cancer Drugs to Next Stage
Bruce V. Bigelow San Diego-based Tracon Pharmaceuticals, which raised $27 million in a Series B financing round in September, plans to raise a total of $57.5 million in (Read more...)
View ArticleGlaucoma Race Heats Up, But Inotek Cuts Back its IPO to $40M
Ben Fidler Inotek Pharmaceuticals is about to make its Nasdaq debut, but not at the price it was shooting for. The Lexington, MA-based company priced its IPO late Monday, selling (Read more...)
View ArticleCompanion Diagnostic Specialist AltheaDx Withdraws IPO
Bruce V. Bigelow San Diego’s AltheaDx, which offers a series of molecular diagnostic tests that enable doctors to identify the optimal drugs for treating patients, yesterday withdrew its plans for...
View Article
More Pages to Explore .....